{"title":"Insulin-like growth factor-neutralizing antibodies for cancer therapy.","authors":"Qi Zhao, Jia Shen","doi":"10.1093/jleuko/qiaf122","DOIUrl":null,"url":null,"abstract":"<p><p>The insulin-like growth factor (IGF) axis is crucial for regulating cell growth, survival, and differentiation. While therapies targeting the IGF-1R have shown limited clinical success as single agents, the abnormal expression of its ligands, IGF-I and IGF-II, has been shown to contribute significantly to resistance against IGF-1R-targeted treatments. This review explores recent advancements in neutralizing antibodies against IGF-I and/or IGF-II, including monoclonal antibody, bispecific antibodies, and engineered antibody domains. These approaches have demonstrated promising therapeutic potential in preclinical cancer models and are currently being evaluated in early clinical trials. Furthermore, we address the rationale for future combination strategies to overcome treatment resistance.</p>","PeriodicalId":16186,"journal":{"name":"Journal of Leukocyte Biology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Leukocyte Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jleuko/qiaf122","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The insulin-like growth factor (IGF) axis is crucial for regulating cell growth, survival, and differentiation. While therapies targeting the IGF-1R have shown limited clinical success as single agents, the abnormal expression of its ligands, IGF-I and IGF-II, has been shown to contribute significantly to resistance against IGF-1R-targeted treatments. This review explores recent advancements in neutralizing antibodies against IGF-I and/or IGF-II, including monoclonal antibody, bispecific antibodies, and engineered antibody domains. These approaches have demonstrated promising therapeutic potential in preclinical cancer models and are currently being evaluated in early clinical trials. Furthermore, we address the rationale for future combination strategies to overcome treatment resistance.
期刊介绍：
JLB is a peer-reviewed, academic journal published by the Society for Leukocyte Biology for its members and the community of immunobiologists. The journal publishes papers devoted to the exploration of the cellular and molecular biology of granulocytes, mononuclear phagocytes, lymphocytes, NK cells, and other cells involved in host physiology and defense/resistance against disease. Since all cells in the body can directly or indirectly contribute to the maintenance of the integrity of the organism and restoration of homeostasis through repair, JLB also considers articles involving epithelial, endothelial, fibroblastic, neural, and other somatic cell types participating in host defense. Studies covering pathophysiology, cell development, differentiation and trafficking; fundamental, translational and clinical immunology, inflammation, extracellular mediators and effector molecules; receptors, signal transduction and genes are considered relevant. Research articles and reviews that provide a novel understanding in any of these fields are given priority as well as technical advances related to leukocyte research methods.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
